

Diese Meldung kann unter <http://www.presseportal.de/pm/19995/1674575/eans-news-november-aktiengesellschaft-new-tests-for-diagnosis-of-borreliosis-approved-for-use-as-ce> abgerufen werden.

## novemberAG

EANS-News: november Aktiengesellschaft  
New Tests for Diagnosis of Borreliosis  
approved for use as CE IVD Products

01.09.2010 - 15:31 Uhr, november Aktiengesellschaft

Additional CE certified tests from PROGEN / Multimatrix for a two-step diagnostic of Lyme Borreliosis are approved for laboratory diagnosis

-----  
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.

----- New  
Products

Subtitle: Additional CE certified tests from PROGEN / Multimatrix for a two-step diagnostic of Lyme Borreliosis are approved for laboratory diagnosis

Köln, Heidelber, Regensburg, Germany (euro adhoc) - PROGEN Biotechnik / Multimatrix, a 100% subsidiary of november AG, are supplementing their multiplex product line and offer now new additional CE marked tests for the laboratory diagnosis of Lyme borreliosis. The requirements for the diagnosis of Lyme borreliosis established by the National Reference Centre for Lyme borreliosis stipulate a two-step diagnostic procedure. Now the PROGEN/Multimatrix Luminex-based tests can implement these requirements. In addition to our confirmation assays (Borrelia IgM and IgG) new Borrelia Screening IgG and IgM Tests are now available for the first step of the diagnostic procedure. These tests allow for an automated, quantitative and sensitive detection of specific IgM and IgG antibodies in human samples. Also, in cases of suspected Lyme neuroborreliosis the Borrelia IgG and IgM Test as well as the Screening IgG Test are applicable for the detection of specific antibodies in cerebrospinal fluid. The PROGEN / Multimatrix multiplex tests for the laboratory diagnosis of Lyme borreliosis are a cost-effective alternative to conventional tests and offer an improved diagnostic reliability for both levels of the diagnostic procedure.

Borreliosis: Lyme borreliosis is the most common tick-borne infectious disease in the Northern hemisphere. In most European endemic regions, 20-40% of the tick vector Ixodes ricinus carry at least one of the three known pathogenic bacteria species Borrelia afzelii, Borrelia garinii, and the most common pathogen, Borrelia burgdorferi sensu stricto. Clinical symptoms and diagnosis of Lyme borreliosis is a multi-systemic disease with initial manifestations limited to characteristic ring-shaped skin lesions (erythema migrans), which can progress to systemic infection. The course of disease is divided into 3 stages (I-III). The clinical symptoms of Lyme disease are heterogeneous and depend on the tropism of the infectious agent. Preferential targets of the pathogen are connective tissue of skin and joints, and the nervous system. A correlation between individual Borrelia species and defined clinical symptoms has been observed. In serum IgM antibodies are usually not detectable until week 3 after infection.

Companies: november AG ( [www.november.eu](http://www.november.eu)) is an investment and holding company, listed in the prime standard of the regulated market of the German stock exchange (Deutsche Börse), with special focus on medical technology, biotechnology and environmental technologies and a 100% shareholder of the PROGEN Biotechnik GmbH. PROGEN Biotechnik GmbH, located in Heidelberg, Germany, ( [www.progen.de](http://www.progen.de)) is EN ISO 13485:2007 certified and a manufacturer of in vitro diagnostics (Borreliosis, Hanta-Virus, FSME) and research products (antibodies, polypeptides, AAV, hyperphage) as well as specialist for the manufacturing of multiplex assays in bead-technology used for the Luminex® platform. The company is main shareholder of Multimatrix GmbH based in Regensburg, Germany ( [www.multimatrix.com](http://www.multimatrix.com)). PROGEN is a member of the VDGH, a German association of diagnostic manufacturers.

end of announcement euro adhoc

----- Further  
inquiry note:

Dr. Dirk Zurek  
CEO  
Tel.: +49 (0) 221 82200 520 10  
E-Mail: [ir@november.de](mailto:ir@november.de)

Branche: Biotechnology  
ISIN: DE000A0Z24E9  
WKN: A0Z24E

Index: CDAX, Prime All Share, Technology All Share  
Börsen: Frankfurt / regulated dealing/prime standard  
Berlin / free trade  
Stuttgart / free trade  
Düsseldorf / free trade  
Hannover / free trade  
München / free trade

Originaltext: november Aktiengesellschaft  
ISIN: DE000A0Z24E9  
Pressemappe: <http://www.presseportal.de/pm/19995/november-aktiengesellschaft>  
Pressemappe als RSS: [http://presseportal.de/rss/pm\\_19995.rss2](http://presseportal.de/rss/pm_19995.rss2)